Catheter Precision (NYSEAMERICAN:VTAK) Stock Price Down 2.2% – Here’s Why

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) fell 2.2% during mid-day trading on Tuesday . The company traded as low as $0.9496 and last traded at $0.9971. 79,507 shares traded hands during mid-day trading, a decline of 12% from the average session volume of 90,467 shares. The stock had previously closed at $1.02.

Catheter Precision Trading Down 2.2%

The stock’s fifty day simple moving average is $0.93 and its 200-day simple moving average is $1.53. The firm has a market cap of $2.68 million, a PE ratio of -0.08 and a beta of -1.01. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.06 and a quick ratio of 0.06.

Catheter Precision (NYSEAMERICAN:VTAK) last posted its quarterly earnings results on Monday, May 18th. The company reported ($1.39) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($20.90) by $19.51. The business had revenue of $0.43 million during the quarter, compared to analysts’ expectations of $1.60 million. Catheter Precision had a negative net margin of 1,297.56% and a negative return on equity of 76.51%.

Institutional Trading of Catheter Precision

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC acquired a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned 2.08% of Catheter Precision at the end of the most recent reporting period. 20.34% of the stock is currently owned by institutional investors.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.